Skip to main content
SpringerLink
Log in

Zytokintherapien bei malignen Hauttumoren

  • Chapter
Therapie der Hautkrankheiten

  • 90 Accesses

Zusammenfassung

Als Zytokine werden im allgemeinen Proteine mit niedrigem Molekulargewicht bezeichnet, die vor allem von Zellen des Immunsystems synthetisiert werden. Zytokine binden spezifisch mit hoher Affinität an Rezeptoren der Zielzellen und regulieren ihre Proliferation, Differenzierung und funktionelle Aktivierung. Im Gegensatz zu endokrinen Hormonen werden sie nicht von spezialisierten Drüsen synthetisiert, sondern von Zellen unterschiedlichen Gewebsursprungs. Sie sind oft im Serum nicht nachweisbar und wirken auf ihre Zielzellen parakrin oder autokrin. Darunter wird verstanden, daß die Zytokine entweder von Zellen in der unmittelbaren Umgebung der Zielzellen synthetisiert werden und auf ihre Nachbarzellen (parakrin) wirken, oder aber durch die Zelle selbst, auf die sie einwirken (autokrin), produziert werden. Zytokine spielen eine wesentliche Rolle in der Regulation immunologischer Abwehrmechanismen und somit in den modernen Behandlungsstrategien gegen Tumoren. Eine Reihe von Zytokinen wird inzwischen gentechnologisch hergestellt und steht in ausreichend großen Mengen für therapeutische Zwecke zur Verfügung. Antitumorwirkungen von Zytokinen werden auf verschiedene Weise vermittelt.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 54.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  • Brysk MM, Santschi CH, Bell T et al. (1992) Culture of basal cell carcinoma. J Invest Dermatol 98: 45–49

    PubMed  CAS  Google Scholar 

  • Garbe C, Krasagakis K (1993) Effects of interferons and cytokines on melanoma cells. J Invest Dermatol 100: 239s - 244s

    PubMed  CAS  Google Scholar 

  • Garbe C, Krasagakis K, Zouboulis C et al. (1990) Antitumor activities of Interferon-alpha, -beta and -gamma on malignant melanoma cells in vitro. Changes of proliferation, melanin synthesis and immunophenotype. J Invest Dermatol 95: 231s - 237s

    PubMed  CAS  Google Scholar 

  • Garbe C, Kreuser ED, Zouboulis C et al. (1992) Combined treatment of metastatic melanoma with inter-ferons and cytotoxic drugs. Semin Oncol 19 [suppl 41: 63–69

    Google Scholar 

  • Krasagakis K, Garbe C, Kruger S, Orfanos CE (1991) Effects of interferons on cultured human melanocytes in vitro: interferon-beta but not-alpha or -gamma inhibit proliferation and all interferons significantly modulate the cell phenotype. J Invest Dermatol 97: 364–372

    PubMed  CAS  Google Scholar 

  • Altomare GF, Capella GL, Pigatto PD, Finzi AF (1993) Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides. Int J Dermatol 32: 138–141

    PubMed  CAS  Google Scholar 

  • Bunn PA, Foon KA, Ihde DC et al. (1984) Recombinant leucocyte A interferon: an active agent in advanced cutaneous T-cell lymphomas. Ann Intern Med 101: 481–187

    Google Scholar 

  • Bunn PA, Ihde DC, Foon KA (1986) The role of recombinant interferon alfa-2a in the therapy of cutaneous T-cell lymphomas. Cancer 57: 1689–1695

    PubMed  Google Scholar 

  • Celerier P, Fleischmann M, Basset Seguin N et al. (1993) In vitro induction of basal keratinocyte MY7 antigen expression in cutaneous T-cell lymphoma is associated with response to interferon-alfa therapy. Arch Dermatol 129: 1136–1140

    PubMed  CAS  Google Scholar 

  • Dreno B, Fleischmann M, Valard S et al. (1992) Induction of myelo-monocytic My7 antigen (CD13) expression by interferon-alpha in basal cells of cutaneous T-cell lymphomas. Br J Dermatol 126: 320–323

    PubMed  CAS  Google Scholar 

  • Dreno B, Celerier P, Litoux P (1993) Roferon-A in combination with Tigason in cutaneous T-cell lymphomas. Acta Haematol 89 [suppl 1]: 28–32

    PubMed  Google Scholar 

  • Kohn EC, Steis RG, Sausville EA et al. (1990) Phase II trial of intermittent high-dose recombinant interferon alfa-2a in mycosis fungoides and the Sézary syndrome. J Clin Oncol 8: 155–160

    PubMed  CAS  Google Scholar 

  • Kuzel TM, Gilyon K, Springer E et al. (1990) Interferon alfa-2a combined with phototherapy in the treatment of cutaneous T-cell lymphoma. J Natl Cancer Inst 82: 203–207

    PubMed  CAS  Google Scholar 

  • Kuzel TM, Roenigk HH Jr, Samuelson E, Rosen ST (1992) Suppression of anti-interferon alpha-2a antibody formation in patients with mycosis fungoides by exposure to long-wave UV radiation in the A range and methoxsalen ingestion. J Natl Cancer Inst 84: 119–121

    PubMed  CAS  Google Scholar 

  • Mostow EN, Neckel SL, Oberhelman L et al. (1993) Complete remissions in psoralen and UV-A ( PUVA)refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA. Arch Dermatol 129: 747–52

    PubMed  CAS  Google Scholar 

  • Nicolas JF, Balblanc JC, Frappaz A et al. (1989) Treatment of cutaneous T cell lymphoma with intermediate doses of interferon alpha 2a. Dermatologica 179: 34–37

    PubMed  CAS  Google Scholar 

  • Olsen EA, Rosen ST, Vollmer RT et al. (1989) Interferon alfa-2a in the treatment of cutaneous T cell lymphoma. J Am Acad Dermatol 20: 395–407

    PubMed  CAS  Google Scholar 

  • Otte HG, Herges A, Stadler R (1992) Kombinationstherapie mit Interferon alfa 2a and PUVA bei kutanen T-Zell-Lymphomen. Hautarzt 43: 695–699

    PubMed  CAS  Google Scholar 

  • Roenigk HH Jr, Kuzel TM, Skoutelis AP et al. (1990) Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma. J Invest Dermatol 95 [suppl 6]: 198–205

    Google Scholar 

  • Ross C, Tingsgaard P, Jorgensen H, Vejlsgaard GL (1993) Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol 51: 63–72

    PubMed  CAS  Google Scholar 

  • Simoni R, Cavalieri R, Coppola G et al. (1987) Recombinant leukocyte interferon alfa-2a in the treatment of mycosis fungoides. J Biol Regul Homeost Agents 1: 93–99

    PubMed  CAS  Google Scholar 

  • Springer EA, Kuzel TM, Variakojis D et al. (1993) Correlation of clinical responses with immunologic and morphologic characteristics in patients with cutaneous T-cell lymphoma treated with interferon alfa-2a. J Am Acad Dermatol 29: 42–46

    PubMed  CAS  Google Scholar 

  • Thestrup Pedersen K, Hammer R, Kaltoft K et al. (1988) Treatment of mycosis fungoides with recombinant interferon-alpha 2a2 alone and in combination with etretinate. Br J Dermatol 118: 811–818

    PubMed  CAS  Google Scholar 

  • Tura S, Mazza P, Zinzani PL et al. (1987) Alpha recombinant interferon in the treatment of mycosis fungoides ( MF ). Haematologica 72: 337–340

    PubMed  CAS  Google Scholar 

  • Vegna ML, Papa G, Defazio D et al. (1990) Interferon alpha-2a in cutaneous T-cell lymphoma. Eur J Haematol (suppl) 52: 32–35

    CAS  Google Scholar 

  • Zachariae H, Thestrup Pedersen K (1990) Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma. J Invest Dermatol 95 [suppl 6]: 206–208

    Google Scholar 

  • Abrams DI, Volberding PA (1986) Alpha interferon therapy of AIDS-associated Kaposi’s sarcoma. Semin Oncol 13 [suppl 2]: 43–47

    PubMed  CAS  Google Scholar 

  • Baumann R, Tauber MG, Opravil M et al. (1991) Combined treatment with zidovudine and lymphoblast interferon-alpha in patients with HIV-related Kaposi’s sarcoma. Klin Wochenschr 69: 360–367

    PubMed  CAS  Google Scholar 

  • Davey RT Jr, Davey VJ, Metcalf JA et al. (1991) A phase I/II trial of zidovudine, interferon-alpha, and granulocyte-macrophage colony-stimulating factor in the treatment of human immunodeficiency virus type 1 infection. J Infect Dis 164: 43–52

    PubMed  Google Scholar 

  • Fischl MA (1991) Antiretroviral therapy in combination with interferon for AIDS-related Kaposi’s sarcoma. Am J Med 90: 2s - 7s

    PubMed  CAS  Google Scholar 

  • Fischi MA, Uttamchandani RB, Resnick L et al. (1991) A phase I study of recombinant human interferon-alpha 2a or human lymphoblastoid interferon-alpha n1 and concomitant zidovudine in patients with AIDS-related Kaposi’s sarcoma. J Acquir Immune Defic Syndr 4: 1–10

    Google Scholar 

  • Ganser A, Brucher W, Brodt HR et al. (1986) Treatment of AIDS-related Kaposi’s sarcoma with recombinant gamma-interferon. Onkologie 9: 163–166

    PubMed  CAS  Google Scholar 

  • Gelmann EP, Preble OT, Steis R et al. (1985) Human lymphoblastoid interferon treatment of Kaposi’s sarcoma in the acquired immune deficiency syndrome. Clinical response and prognostic parameters. Am J Med 78: 737–741

    PubMed  CAS  Google Scholar 

  • Groopman JE, Gottlieb MS, Goodman J et al. (1984) Recombinant alpha-2 interferon therapy for Kaposi’s sarcoma associated with the acquired immunodeficiency syndrome. Ann Intern Med 100: 671–676

    PubMed  CAS  Google Scholar 

  • Heagy W, Groopman J, Schindler J, Finberg R (1990) Use of IFN-gamma in patients with AIDS. J Acquir Immune Defic Syndr 3: 584–590

    PubMed  CAS  Google Scholar 

  • Kern P, Meigel W, Racz P et al. (1987) Interferon alpha in the treatment of AIDS-associated Kaposi’s sarcoma. Onkologie 10: 50–52

    PubMed  CAS  Google Scholar 

  • Kovacs JA, Deyton L, Davey R et al. (1989) Combined zidovudine and interferon-alpha therapy in patients with Kaposi sarcoma and the acquired immunodeficiency syndrome ( AIDS ). Ann Intern Med 111: 280–287

    PubMed  CAS  Google Scholar 

  • Krigel RL, Odajnyk CM, Laubenstein LJ et al. (1985) Therapeutic trial of interferon-gamma in patients with epidemic Kaposi’s sarcoma. J Biol Response Mod 4: 358–364

    PubMed  CAS  Google Scholar 

  • Krigel RL, Padavic Shaller KA, Rudolph AR et al. (1989) Exacerbation of epidemic Kaposi’s sarcoma with a combination of interleukin-2 and beta-interferon: results of a phase 2 study. J Biol Response Mod 8: 359–365

    PubMed  CAS  Google Scholar 

  • Krown SE, Real FX, Cunningham Rundles S et al. (1983) Preliminary observations on the effect of recombinant leukocyte A interferon in homosexual men with Kaposi’s sarcoma. N Engl J Med 308: 1071–1076

    PubMed  CAS  Google Scholar 

  • Lane HC, Davey RT Jr, Sherwin SA et al. (1989) A phase I trial of recombinant human interferon-gamma in patients with Kaposi’s sarcoma and the acquired immunodeficiency syndrome ( AIDS ). J Clin Immunol 9: 351–361

    PubMed  CAS  Google Scholar 

  • Miles SA, Wang HJ, Cortes E et al. (1990) Beta-interferon therapy in patients with poor-prognosis Kaposi sarcoma related to the acquired immunodeficiency syndrome (AIDS). A phase II trial with preliminary evidence of antiviral activity and low incidence of opportunistic infections. Ann Intern Med 112: 582–589

    PubMed  CAS  Google Scholar 

  • Plettenberg A, Kern P, Dietrich M, Meigel W (1990) Rekombinantes Interferon alpha 2A in der Behandlung des HIV-assoziierten Kaposi-Sarkoms. Langzeitergebnisse. Med Klin 85: 647–652

    CAS  Google Scholar 

  • Real FX, Oettgen HF, Krown SE (1986) Kaposi’s sarcoma and the acquired immunodeficiency syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 4: 544–551

    PubMed  CAS  Google Scholar 

  • Rios A, Mansell PW, Newell GR et al. (1985) Treatment of acquired immunodeficiency syndrome–related Kaposi’s sarcoma with lymphoblastoid interferon. J Clin Oncol 3: 506–512

    PubMed  CAS  Google Scholar 

  • Rozenbaum W, Gharakhanian S, Navarette MS et al. (1990) Long-term follow-up of 120 patients with AIDS-related Kaposi’s sarcoma treated with interferon alpha-2a. J Invest Dermatol 95 [suppl 6]: 161–165

    Google Scholar 

  • Sawyer LA, Metcalf JA, Zoon KC et al. (1990) Effects of interferon-alpha in patients with AIDS-associated Kaposi’s sarcoma are related to blood interferon levels and dose. Cytokine 2: 247–252

    PubMed  CAS  Google Scholar 

  • Scadden DT, Bering HA, Levine JD et al. (1991) GMCSF as an alternative to dose modification of the combination zidovudine and interferon-alpha in the treatment of AIDS-associated Kaposi’s sarcoma. Am J Clin Oncol 14 [suppl 1]: 40–44

    Google Scholar 

  • Scadden DT, Bering HA, Levine JD et al. (1991) Granulocyte-macrophage colony-stimulating factor mitigates the neutropenia of combined interferon alfa and zidovudine treatment of acquired immune deficiency syndrome-associated Kaposi’s sarcoma. J Clin Oncol 9: 802–808

    PubMed  CAS  Google Scholar 

  • Schaart FM, Bratzke B, Ruszczak Z et al. (1991) Longterm therapy of HIV-associated Kaposi’s sarcoma with recombinant interferon alpha-2a. Br J Dermatol 124: 62–68

    PubMed  CAS  Google Scholar 

  • Schröder K, Garbe C, Waibel M et al. (1992) Granulozyten-Koloniestimulierender Faktor (G-CSF) in der Behandlung von Patienten mit HIV-assoziiertem mukokutanem Kaposi-Sarkom. Erfolgreicher Einsatz bei virus-bzw. medikamenteninduzierter Leukopenie. Hautarzt 43: 700–706

    PubMed  Google Scholar 

  • Stadler R, Bratzke B, Schaart F, Orfanos CE (1990) Long-term combined rIFN-alpha-2a and zidovudine therapy for HIV-associated Kaposi’s sarcoma: clinical consequences and side effects. J Invest Dermatol 95 [suppl 6]: 170–175

    Google Scholar 

  • Volberding P, Valero R, Rothman J, Gee G (1984) Alpha interferon therapy of Kaposi’s sarcoma in AIDS. Ann N Y Acad Sci 437: 439–116

    PubMed  CAS  Google Scholar 

  • Volberding PA, Mitsuyasu RT, Golando JP, Spiegel RJ (1987) Treatment of Kaposi’s sarcoma with interferon alfa-2b (Intron A). Cancer 59 [suppl 3]: 620–625

    PubMed  CAS  Google Scholar 

  • Abdi EA, Tan YH, McPherson TA (1988) Natural human interferon-beta in metastatic malignant melanoma. A phase II study. Acta Oncol 27: 815–817

    PubMed  CAS  Google Scholar 

  • Atzpodien J, Korfer A, Franks CR et al. (1990) Home therapy with recombinant interleukin-2 and interferon-a-2b in advanced human malignancies. Lancet 335: 1509–1512

    PubMed  CAS  Google Scholar 

  • Bajetta E, Negretti E, Giannotti B et al. (1990) Phase II study of interferon-alpha-2a and dacarbazine in advanced melanoma. Am J Clin Oncol 13: 405–409

    PubMed  CAS  Google Scholar 

  • Beiteke U, Ruppert P, Garbe C et al. (1993) Adjuvante Therapie des primaren malignen Melanoms mit natürlichem humanen Interferon-beta. Signifikanter Überlebensvorteil bei 96 behandelten Patienten im Vergleich zu 288 unbehandelten Symptomenzwillingen. Hautarzt 44: 365–371

    PubMed  CAS  Google Scholar 

  • Breier S, Pensel R, Roffe C et al. (1990) High dose DTIC with recombinant human interferon alpha-2b (rhifn2b) for the treatment of metastatic malignant melanoma ( MMM ). Proc Ann Meet Am Soc Clin Oncol 9: A1090

    Google Scholar 

  • Brunda MJ, Luistro L, Warrier RR et al. (1993) Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 178: 1223–30

    PubMed  CAS  Google Scholar 

  • Castello G, Comella P, Manzo T et al. (1993) Immunological and,clinical effects of intramuscular rIFN alpha-2a and low dose subcutaneous rIL-2 in patients with advanced malignant melanoma. Melanoma Res 3: 43–49

    PubMed  CAS  Google Scholar 

  • Demchak PA, Mier JW, Robert NJ et al. (1990) Interleukin-2 and high-dose cisplatin in patients with metastatic melanoma: a pilot study. J Clin Oncol 9: 1821–1830

    Google Scholar 

  • Dillman RO, Oldham RK, Barth NM et al. (1990) Recombinant interleukin-2 and adoptive immunotherapy alternated with dacarbazine therapy in melanoma: a National Biotherapy Study Group trial. J Natl Cancer Inst 82: 1345–1349

    PubMed  CAS  Google Scholar 

  • Dillman RO, Church C, Oldham RK et al. (1993) Inpatient continuous-infusion interleukin-2 in 788 patients with cancer. The National Biotherapy Study Group experience. Cancer 71: 2358–2370

    PubMed  CAS  Google Scholar 

  • Dummer R, Muller W, Nestle F et al. (1991) Formation of neutralizing antibodies against natural interferon-beta, but not against recombinant interferon-gamma during adjuvant therapy for high-risk malignant melanoma patients. Cancer 67: 2300–2304

    PubMed  CAS  Google Scholar 

  • Elsässer Beile U, Garbe C, Stadler R et al. (1989) Adjuvante Therapie mit rekombiniertem Interferon alfa-2a beim metastasierten malignen Melanom. Hautarzt 40: 266–270

    PubMed  Google Scholar 

  • Falkson CI, Falkson G, Falkson HC (1991) Improved results with the addition of recombinant interferon alpha-2b to dacarbazine in treatment of patients with metastatic malignant melanoma. J Clin Oncol 9: 1403–1408

    PubMed  CAS  Google Scholar 

  • Fierlbeck G, d’Hoedt B, Stroebel Wet al. (1992) Intraläsionale Therapie von Melanommetastasen mit rekombinantem Interferon-beta. Hautarzt 43: 16–21

    PubMed  CAS  Google Scholar 

  • Flaherty LE, Redman BG, Chabot GG et al. (1990) A phase I-II study of dacarbazine in combination with outpatient interleukin-2 in metastatic malignant melanoma. Cancer 65: 2471–2477

    PubMed  CAS  Google Scholar 

  • Garbe C, Krasagakis K, Zouboulis C et al. (1990) Anti tumor activities of Interferon-alpha, -beta and -gamma on malignant melanoma cells in vitro. Changes of proliferation, melanin synthesis and immunophenotype. J Invest Dermatol 95: 231s - 237s

    PubMed  CAS  Google Scholar 

  • Garbe C, Krasagakis K (1993) Effects of interferons and cytokines on melanoma cells. J Invest Dermatol 100: 239s - 244s

    PubMed  CAS  Google Scholar 

  • Garbe C, Zouboulis ChC, Stadler R et al. (1994) Prolongation of life in stage IV melanoma by combined treatment with IFN-a-2a and vindesine. Pigment Cell Res 6: 278

    Google Scholar 

  • Gundersen S, Flokkmann A (1989) Interferon in combination with vinblastine in advanced malignant melanoma. A phase I-II study. Cancer 64: 1617–1619

    PubMed  CAS  Google Scholar 

  • Hamblin TJ, Davies B, Sadullah S et al. (1991) A phase II study of the treatment of metastatic malignant melanoma with a combination of dacarbazine, cisplatin, interleukin-2(IL-2) and alfa-interferon ( IFN ). Proc Ann Meet Am Soc Clin Oncol 10: A1029

    Google Scholar 

  • Hersey P, McLeod RC, Thomson DB (1989) Phase I/II study of tolerability and efficacy of recombinant interferon (Roferon) with dacarbazine (DTIC) in advanced malignant melanoma. J Interferon Res 9 [suppl 2]: 118

    Google Scholar 

  • Johns TG, Mackay IR, Callister KA et al. (1992) Anti-proliferative potencies of interferons on melanoma cell lines and xenografts: higher efficacy of interferon beta. J Natl Cancer Inst 84: 1185–90

    PubMed  CAS  Google Scholar 

  • Keilholz U, Scheibenbogen C, Tilgen W et al. (1993) Interferon-alpha and interleukin-2 in the treatment of metastatic melanoma. Comparison of two phase II trials. Cancer 72: 607–614

    PubMed  CAS  Google Scholar 

  • Kellokumpu-Lehtinen P, Nordman E, Toivanen A (1989) Combined interferon and vinblastine treatment of advanced melanoma: Evaluation of the treatment results and the effects of treatment on immunological functions. Cancer Immunol Immunother 28: 213–217

    PubMed  CAS  Google Scholar 

  • Kerr R, Pippen P, Mennel R, Jones S (1989) Treatment of metastatic malignant melanoma with a combination of interferon-alpha-2a (ifn-alpha-2a, Roferon) and dacarbazine ( DTIC ). Proc Ann Meet Am Soc Clin Oncol 8: A1122

    Google Scholar 

  • Landthaler M, Braun-Falco 0 (1989) Adjuvant therapy of high-risk malignant melanoma patients with gamma interferon. J Am Acad Dermatol 20: 687–688

    PubMed  CAS  Google Scholar 

  • Legha S, Plager C, Ring S et al. (1992) A phase II study of biochemotherapy using interleukin-2 (IL-2) + Interferon alfa-2a (IFN) in combination with cisplatin (C) vinblastine (V) and DTIC ( D) in patients with metastatic melanoma. Proc Ann Meet Am Soc Clin Oncol 11: A1179

    Google Scholar 

  • Lollini PL, De; Giovanni C, Nicoletti G et al. (1990) Enhancement of experimental metastatic ability by tumor necrosis factor-alpha alone or in combination with interferon-gamma. Clin Exp Metastasis 8: 215–224

    Google Scholar 

  • Margolin K, Doroshow J, Akman S et al. (1990) Treatment (RX) of advanced melanoma with cis-diamminedichloroplatinum ( CDDP) and alpha interferon (alpha IFN ). Proc Ann Meet Am Soc Clin Oncol 9: A1074

    Google Scholar 

  • Meyskens FL Jr, Kopecky K, Samson M et al. (1990) Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma [letter] J Natl Cancer Inst 82: 1071

    PubMed  Google Scholar 

  • Mulder NH, Schraffordt-Koops H, Sleijfer DT et al. (1990) Dacarbazine and alpha-interferon for disseminated malignant melanoma. Proc Ann Meet Am Soc Clin Oncol 9: A1083

    Google Scholar 

  • Oratz R, Dugan M, Walsh C et al. (1989) Phase II trial of r-alpha 2b-interferon (IFN) and cisplatin (CDDP) in metastatic malignant melanoma ( MM ). Proc Ann Meet Am Soc Clin Oncol 8: A1123

    Google Scholar 

  • Osanto S, Jansen R, Naipal AM et al. (1989) In vivo effects of combination treatment with recombinant interferon-gamma and -alpha in metastatic melanoma. Int J Cancer 43: 1001–1006

    PubMed  CAS  Google Scholar 

  • Pyrhonen S, Hahka Kemppinen M, Muhonen T (1992) A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 10: 1919–1926

    PubMed  CAS  Google Scholar 

  • Pyrhonen S, Kouri M, Holsti LR, Cantell K (1992) Disease stabilization by leukocyte alpha interferon and survival of patients with metastatic melanoma. Oncology 49: 22–26

    PubMed  CAS  Google Scholar 

  • Richards J, Mehta N, Schroeder L, Dordal A (1992) Sequential chemotherapy/immunotherapy for metastatic melanoma. Proc Ann Meet Am Soc Clin Oncol 11: A1189

    Google Scholar 

  • Richards JM, Mehta N, Ramming K, Skosey P (1992) Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 10: 1338–1343

    PubMed  CAS  Google Scholar 

  • Richner J, Cerny T, Joss RA et al. (1990) A phase II study of continuous sc alpha-2b interferon (IFN) combined with cisplatin (CDDP) in advanced malignant melanoma ( MM ). Proc Ann Meet Am Soc Clin Oncol 9: A1085

    Google Scholar 

  • Ron IG, Inbar MJ, Gutman M et al. (1993) Recombinant interferon alpha-2a in combination with dacarbazine in the treatment of metastatic malignant melanoma: analysis of long-term responding patients. Cancer Immunol Immunother 37: 61–66

    PubMed  CAS  Google Scholar 

  • Rosenberg SA, Lotze MT, Muul LM et al. (1985) Observations on the systemic administration of autologous lymphokine activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313: 1485–1492

    PubMed  CAS  Google Scholar 

  • Rosenberg SA, Lotze MT, Yang JC et al. (1989) Experience with the use of high dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 210: 474–485

    PubMed  CAS  Google Scholar 

  • Rosenberg SA, Lotze MT, Yang JC et al. (1989) Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7: 1863–1874

    PubMed  CAS  Google Scholar 

  • Schuchter L, McGuire WP, Wohlganger J, Redden T (1989) Sequential treatment of metastatic melanoma with interferon-alpha (IFN) plus cis-platinum ( CDDP ). Proc Ann Meet Am Soc Clin Oncol 8: A1120

    Google Scholar 

  • Sertoli MR, Queirolo P, Bajetta E et al. (1992) Dacarbazine (DTIC) with or without recombinant interferon alpha-2a at different dosages in the treatment of stage IV melanoma patients. Prelimanary results of a randomized trial. Proc Ann Meet Am Soc Clin Oncol 11: A1185

    Google Scholar 

  • Smith KA, Green JA, Eccles JM (1992) Interferon alpha 2a and vindesine in the treatment of advanced malignant melanoma. Eur J Cancer 28: 438–441

    PubMed  CAS  Google Scholar 

  • Stadler R, Garbe C (1991) Disseminated malignant melanoma. New therapeutic approaches. Int J Dermatol 30: 239–242

    PubMed  CAS  Google Scholar 

  • Thomson D, Adena M, McLeod GRC et al. (1992) Interferona-2a (IFN) does not improve response or survival when added to dacarbazine (DTIC) in metastatic melanoma: Results of a multi-institutional Australian randomized trial QMP8704. Proc Ann Meet Am Soc Clin Oncol 11: A1177

    Google Scholar 

  • Whitehead RP, Figlin R, Citron ML et al. (1993) A phase II trial of concomitant human interleukin-2 and interferon-alpha-2a in patients with disseminated malignant melanoma. J Immunother 13: 117–121

    CAS  Google Scholar 

  • Boente P, Sampaio C, Brandao MA et al. (1993) Local peri-lesional therapy with rhGM-CSF for Kaposi’s sarcoma (letter). Lancet 341: 1154

    PubMed  CAS  Google Scholar 

  • Buechner SA (1991) Intralesional interferon alfa-2b in the treatment of basal cell carcinoma. Immunohistochemical study on cellular immune reaction leading to tumor regression. J Am Acad Dermatol 24: 731–734

    PubMed  CAS  Google Scholar 

  • Cornell RC, Greenway HT, Tucker SB et al. (1990) Intralesional interferon therapy for basal cell carcinoma. J Am Acad Dermatol 23: 694–700

    PubMed  CAS  Google Scholar 

  • Edwards L, Tucker SB, Perednia D et al. (1990) The effect of an intralesional sustained-release formulation of interferon alfa-2b on basal cell carcinomas. Arch Dermatol 126: 1029–1032

    PubMed  CAS  Google Scholar 

  • Fierlbeck G, d’Hoedt B, Stroebel Wet al. (1992) Intraläsionale Therapie von Melanommetastasen mit rekombinantem Interferon-beta. Hautarzt 43: 16–21

    PubMed  CAS  Google Scholar 

  • Greenway HT, Cornell RC, Tanner DJ et al. (1986) Treatment of basal cell carcinoma with intralesional interferon. J Am Acad Dermatol 15: 437–443

    PubMed  CAS  Google Scholar 

  • Grob JJ, Collet AM, Munoz MH, Bonerandi JJ (1988) Treatment of large basal-cell carcinomas with intralesional interferon-alpha-2a (letter). Lancet I: 878–879

    Google Scholar 

  • Hauschild A, Petres-Dunsche C (1992) Intraläsionäre Behandlung des klassischen Kaposi-Sarkoms mit Interferon alpha. Hautarzt 43: 789–791

    PubMed  CAS  Google Scholar 

  • Lutzner MA, Blanchet Bardon C, Orth G (1984) Clinical observations, virologic studies, and treatment trials in patients with epidermodysplasia verruciformis, a disease induced by specific human papillomaviruses. J Invest Dermatol 83: 18s - 25s

    PubMed  CAS  Google Scholar 

  • Mozzanica N, Cattaneo A, Boneschi V et al. (1990) Immunohistological evaluation of basal cell carcinoma immunoinfiltrate during intralesional reatment with alpha 2-interferon. Arch Dermatol Res 282: 311–317

    PubMed  CAS  Google Scholar 

  • Tank B, Habets JM, Naafs B et al. (1989) Intralesional reatment of basal cell carcinoma with low-dose recombinant interferon gamma. J Am Acad Dermatol 21: 734–735

    PubMed  CAS  Google Scholar 

  • Wickramasinghe L, Hindson TC, Wacks H (1989) Treatment of neoplastic skin lesions with intralesional interferon. J Am Acad Dermatol 20: 71–74

    PubMed  CAS  Google Scholar 

  • Wussow P v, Block B, Hartmann F, Deicher H (1988) Intralesional interferon-alpha therapy in advanced malignant melanoma. Cancer 61: 1071–1074

    Google Scholar 

  • Antonelli G, Currenti M, Turriziani O, Dianzani F (1991) Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations. J Infect Dis 163: 882–885

    PubMed  CAS  Google Scholar 

  • Bekisz JB, zur Nedden DL, Enterline JC, Zoon KC (1989) Antibodies to interferon-alpha 2 in patients treated with interferon-alpha 2 for hairy cell leukemia. J Interferon Res 9 [suppl 1]: 1–7

    Google Scholar 

  • Budd GT, Osgood B, Barna B et al. (1989) Phase I clinical trial of interleukin 2 and alpha-interferon: toxicity and immunologic effects. Cancer Res 49: 6432–6436

    PubMed  CAS  Google Scholar 

  • Catani L, Gugliotta L, Zauli G et al. (1992) In vitro inhibition of interferon alpha-2a antiproliferative activity by antibodies developed during treatment for essential thrombocythaemia. Haematologica 77: 318–321

    PubMed  CAS  Google Scholar 

  • Cottler Fox M, Torrisi J, Spitzer TR, Deeg HJ (1990) Increased toxicity of total body irradiation in patients receiving interferon for leukaemia (letter). Lancet 335: 174

    PubMed  CAS  Google Scholar 

  • Economou JS, Hoban M, Lee JD et al. (1991) Production of tumor necrosis factor alpha and interferon gamma in interleukin-2-treated melanoma patients: correlation with clinical toxicity. Cancer Immunol Immunother 34: 49–52

    PubMed  CAS  Google Scholar 

  • Fossa SD, Gunderson R, Moe B (1990) Recombinant interferon-alpha combined with prednisone in metastatic renal cell carcinoma. Reduced toxicity without reduction of the response rate-a phase II study. Cancer 65: 2451–2454

    PubMed  CAS  Google Scholar 

  • Freund M, von Wussow P, Diedrich H et al. (1989) Recombinant human interferon (IFN) alpha-2b in chronic myelogenous leukaemia: dose dependency of response and frequency of neutralizing anti-interferon antibodies. Br J Haematol 72: 350–356

    PubMed  CAS  Google Scholar 

  • Liao MJ, Axelrod HR, Kuchler M et al. (1992) Absence of neutralizing antibodies to interferon in condyloma acuminata and cancer patients treated with natural human leukocyte interferon. J Infect Dis 165: 757–760

    PubMed  CAS  Google Scholar 

  • Oberg K, Alm G, Magnusson A et al. (1989) Treatment of malignant carcinoid tumors with recombinant interferon alfa-2b: development of neutralizing interferon antibodies and possible loss of antitumor activity. J Natl Cancer Inst 81: 531–535

    PubMed  CAS  Google Scholar 

  • Prümmer O (1993) Interferon-alpha antibodies in patients with renal cell carcinoma treated with recombinant interferon-alpha-2A in an adjuvant multicenter trial. The Delta-P Study Group. Cancer 71: 1828–1834

    PubMed  Google Scholar 

  • Prümmer O, Seyfarth C, Scherbaum WA et al. (1989) Interferon-alpha antibodies in autoimmune diseases. J Interferon Res 9 [suppl 1]: 67–74

    Google Scholar 

  • Ridolfi R, Maltoni R, Riccobon A et al. (1992) Evaluation of toxicity in 22 patients treated with subcutaneous interleukin-2, alpha-interferon with and without chemotherapy. J Chemother 4: 394–398

    PubMed  CAS  Google Scholar 

  • Ronnblom LE, Janson ET, Perers A et al. (1992) Characterization of anti-interferon-alpha antibodies appearing during recombinant interferon-alpha 2a treatment. Clin Exp Immunol 89: 330–335

    PubMed  CAS  Google Scholar 

  • Ross C, Hansen MB, Schyberg T, Berg K (1990) Auto-antibodies to crude human leucocyte interferon (IFN), native human IFN, recombinant human IFNalpha 2b and human IFN-gamma in healthy blood donors. Clin Exp Immunol 82: 57–62

    PubMed  CAS  Google Scholar 

  • Schechter D, Nagler A (1992) Recombinant interleukin-2 and recombinant interferon alpha immunotherapy cardiovascular toxicity. Am Heart J 123: 1736–1739

    PubMed  CAS  Google Scholar 

  • Schiller JH, Storer B, Paulnock DM et al. (1990) A direct comparison of biological response modulation and clinical side effects by interferon-beta ser, interferon-gamma, or the combination of interferons beta ser and gamma in humans. J Clin Invest 86: 1211–1221

    PubMed  CAS  Google Scholar 

  • Spiegel RJ, Jacobs SL, Treuhaft MW (1989) Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective. J Interferon Res 9 [suppl 1]: 17–24

    Google Scholar 

  • Steinmann GG, God B, Rosenkaimer F et al. (1992) Low incidence of antibody formation due to longterm interferon-alpha 2c treatment of cancer patients. Clin Invest 70: 136–141

    CAS  Google Scholar 

  • Steis RG, Smith JW 2d, Urba WJ et al. (1991) Loss of interferon antibodies during prolonged continuous interferon-alpha 2a therapy in hairy cell leukemia. Blood 77: 792–798

    PubMed  CAS  Google Scholar 

  • Turano A, Caruso A (1993) The role of human autoantibodies against gamma-interferon. J Antimicrob Che-mother 32 [suppl A]: 99–105

    Google Scholar 

  • Visco G, Boumis E, Noto P, Comandini UV (1991) Prevention of side-effects of interferon (letter): Lancet 337: 741

    PubMed  CAS  Google Scholar 

  • Weck PK, Leventhal BG, Brand C, Finter NB (1989) Detection and incidence of neutralizing antibodies to interferon-alpha-n1. J Interferon Res 9 [suppl 1]: 37–43

    Google Scholar 

  • Wit R de, Bakker PJ, Danner SA et al. (1990) Low incidence of anti-interferon-alpha antibodies in patients treated with interferon-alpha-2a for AIDS-associated Kaposi’s sarcoma. Int J STD AIDS 1: 256–258

    PubMed  Google Scholar 

  • Wussow P v, Jakschies D (1990) Interferon-Antikörper–Phantasie oder Faktum? In: Niederle N, Von Wussow P: Interferone: Präklinische and Klinische Befunde. Berlin, Springer-Verlag, S. 79–91

    Google Scholar 

  • Wussow P v, Jakschies D, Freund M et al. (1991) Treatment of anti-recombinant interferon-alpha 2 antibody positive CML patients with natural interferon-alpha. Br J Haematol 78: 210–216

    PubMed  CAS  Google Scholar 

  • Wussow P v, Pralle H, Hochkeppel HK et al. (1991) Effective natural interferon-alpha therapy in recombinant interferon-alpha-resistant patients with hairy cell leukemia. Blood 78: 38–43

    Google Scholar 

  • Crowley NJ, Seigler HF (1993) Possibilities of immunotherapy and gene therapy for malignant melanoma. Semin Surg Oncol 9: 273–278

    PubMed  CAS  Google Scholar 

  • Hill AD, Redmond HP, Croke DT et al. (1992) Cytokines in tumour therapy. Br J Surg 79: 990–997

    PubMed  CAS  Google Scholar 

  • Ogasawara M, Rosenberg SA (1993) Enhanced expression of HLA molecules and stimulation of autologous human tumor infiltrating lymphocytes following transduction of melanoma cells with gamma-interferon genes. Cancer Res 53: 3561–3568

    PubMed  CAS  Google Scholar 

  • Rosenberg SA (1992) Gene therapy for cancer. JAMA 268: 2416–2419

    PubMed  CAS  Google Scholar 

  • Wadler S (1992) The role of interferons in the treatment of solid tumors. Cancer 70 [suppl 4]: 949–958

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitäts-Hautklinik und Poliklinik, Klinikum Benjamin Franklin der Freien Universität Berlin, Hindenburgdamm 30, 12200, Berlin, Deutschland

    Prof. Dr. Prof. h.c. Constantin E. Orfanos & Prof. Dr. Claus Garbe

Authors
  1. Prof. Dr. Prof. h.c. Constantin E. Orfanos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. Claus Garbe
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Orfanos, C.E., Garbe, C. (1995). Zytokintherapien bei malignen Hauttumoren. In: Therapie der Hautkrankheiten. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-97602-5_44

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-97602-5_44

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-97603-2

  • Online ISBN: 978-3-642-97602-5

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation